Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT01685008 is registered in ClinicalTrials.gov with MorphoSys AG as lead sponsor.

NCT NCT01685008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
MorphoSys AG
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2013
Completion date
April 6, 2022
Enrollment
92 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma